ABTECT - Maintenance

Description

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.

Conditions

Ulcerative Colitis

Study Overview

Study Details

Study overview

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.

A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

ABTECT - Maintenance

Condition
Ulcerative Colitis
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama -Birmingham, Birmingham, Alabama, United States, 35233

Dothan

Digestive Health Specialists of the Southeast, Dothan, Alabama, United States, 36305

Guntersville

Lakeview Clinical Research, Guntersville, Alabama, United States, 35976

Litchfield Park

Research Solutions of Arizona, PC, Litchfield Park, Arizona, United States, 85340

Phoenix

Valleywise Health Medical Center, Phoenix, Arizona, United States, 85008

Sun City

GI Alliance, Sun City, Arizona, United States, 85351

Tucson

Del Sol Research Management, LLC, Tucson, Arizona, United States, 85715

Tucson

University of Arizona, Tucson, Arizona, United States, 85724

Little Rock

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States, 72205-7199

Little Rock

Applied Research Center of Arkansas, Little Rock, Arkansas, United States, 72212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    16 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Abivax S.A.,

    Severine Vermeire, MD, PhD, PRINCIPAL_INVESTIGATOR, UZ Leuven, Belgium

    Bruce Sands, MD, PhD, PRINCIPAL_INVESTIGATOR, Mount Sinai Health System Digestive Disease Institute, New York USA

    Study Record Dates

    2030-01